Literature DB >> 27614895

Pramipexole induced place preference after L-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications.

Simon Loiodice1,2, Poppy Winlow3,4, Sarah Dremier3,5, Etienne Hanon3, David Dardou6, Omar Ouachikh6, Aziz Hafidi6, Andre Nogueira da Costa3, Franck Durif6,7.   

Abstract

RATIONALE: Impulsive-compulsive disorders (ICD) in patients with Parkinson's disease (PD) have been described as behavioral or substance addictions including hypersexuality, gambling, or compulsive medication use of the dopamine replacement therapy (DRT).
OBJECTIVES: A remaining challenge is to understand the neuroadaptations leading to reward bias in PD patients under DRT.
METHODS: To this end, the appetitive effect of the D2/D3 agonist pramipexole was assessed after chronic exposure to L-dopa in an alpha-synuclein PD rat model.
RESULTS: Association of progressive nigral loss and chronic L-dopa was required to observe a pramipexole-induced place preference. This behavioral outcome was inhibited by metabotropic glutamate receptor 5 (mGluR5) antagonism while transcriptional profiling highlighted regulations potentially related to the context of psychostimulant addiction.
CONCLUSION: This study provides evidences strongly suggesting that PD-like lesion and L-dopa therapy were concomitant factors involved in striatal remodeling underlying the pramipexole-induced place preference. Molecular and pharmacological data suggest a key involvement of the glutamatergic pathway in this behavioral outcome.

Entities:  

Keywords:  Alpha-synuclein; Impulsive/compulsive disorders; L-dopa; Parkinson’s disease; Pramipexole; Transcriptional profiling

Mesh:

Substances:

Year:  2016        PMID: 27614895     DOI: 10.1007/s00213-016-4430-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  67 in total

1.  Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.

Authors:  Daniel Weintraub; Juergen Koester; Marc N Potenza; Andrew D Siderowf; Mark Stacy; Valerie Voon; Jacqueline Whetteckey; Glen R Wunderlich; Anthony E Lang
Journal:  Arch Neurol       Date:  2010-05

2.  Effects of MPEP on locomotion, sensitization and conditioned reward induced by cocaine or morphine.

Authors:  Volker Herzig; Werner J Schmidt
Journal:  Neuropharmacology       Date:  2004-12       Impact factor: 5.250

3.  The dopamine D2 receptor agonists, quinpirole and bromocriptine produce conditioned place preferences.

Authors:  D C Hoffman; P R Dickson; R J Beninger
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1988       Impact factor: 5.067

4.  Effects of pramipexole on the reinforcing effectiveness of stimuli that were previously paired with cocaine reinforcement in rats.

Authors:  Gregory T Collins; Alyssa R Cunningham; Jianyong Chen; Shaomeng Wang; Amy H Newman; James H Woods
Journal:  Psychopharmacology (Berl)       Date:  2011-06-24       Impact factor: 4.530

5.  Cocaine-induced chromatin remodeling increases brain-derived neurotrophic factor transcription in the rat medial prefrontal cortex, which alters the reinforcing efficacy of cocaine.

Authors:  Ghazaleh Sadri-Vakili; Vidhya Kumaresan; Heath D Schmidt; Katie R Famous; Prianka Chawla; Fair M Vassoler; Ryan P Overland; Eva Xia; Caroline E Bass; Ernest F Terwilliger; R Christopher Pierce; Jang-Ho J Cha
Journal:  J Neurosci       Date:  2010-09-01       Impact factor: 6.167

6.  Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism.

Authors:  Abigail M Brown; Ariel Y Deutch; Roger J Colbran
Journal:  Eur J Neurosci       Date:  2005-07       Impact factor: 3.386

Review 7.  The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders.

Authors:  P Sokoloff; J Diaz; B Le Foll; O Guillin; L Leriche; E Bezard; C Gross
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-02       Impact factor: 4.388

Review 8.  Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex.

Authors:  Satoshi Ikemoto
Journal:  Brain Res Rev       Date:  2007-05-17

9.  Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia.

Authors:  Christine Konradi; Jenny E Westin; Manolo Carta; Molly E Eaton; Katarzyna Kuter; Andrzej Dekundy; Martin Lundblad; M Angela Cenci
Journal:  Neurobiol Dis       Date:  2004-11       Impact factor: 5.996

10.  Reinforcing properties of Pramipexole in normal and parkinsonian rats.

Authors:  Michel Engeln; Serge H Ahmed; Caroline Vouillac; François Tison; Erwan Bezard; Pierre-Olivier Fernagut
Journal:  Neurobiol Dis       Date:  2012-08-23       Impact factor: 5.996

View more
  3 in total

Review 1.  Impulse control disorders in Parkinson's disease.

Authors:  Ana Marques; Franck Durif; Pierre-Olivier Fernagut
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

2.  Effect of Levodopa on Reward and Impulsivity in a Rat Model of Parkinson's Disease.

Authors:  Miguel M Carvalho; Filipa L Campos; Mariana Marques; Carina Soares-Cunha; Nikolaos Kokras; Christina Dalla; Hugo Leite-Almeida; Nuno Sousa; António J Salgado
Journal:  Front Behav Neurosci       Date:  2017-08-08       Impact factor: 3.558

Review 3.  Impulse Control Disorders in Parkinson's Disease: From Bench to Bedside.

Authors:  Andrea Augustine; Catharine A Winstanley; Vaishnav Krishnan
Journal:  Front Neurosci       Date:  2021-03-12       Impact factor: 4.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.